Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical Policymclaren health plan GLP-1 Coverage Prior Auth | Op…
    Ask Trek AI about this page
    Modifiedmclaren health planPolicy MSA 21-49

    Update of Pharmacy Drug Coverage for Treatment of Obesity (GLP-1 receptor agonist medications)

    Customize your policy alerts

    Sign up for mclaren health plan Policy MSA 21-49 alerts

    Get alerted when Policy MSA 21-49 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Updates Medicaid pharmacy coverage and prior authorization requirements for GLP-1 receptor agonist medications when prescribed solely for treatment of obesity; affects prescribers, pharmacies, and Medicaid beneficiaries covered under the referenced plan.

    Policy Summary
    Payermclaren health plan
    PolicyUpdate of Pharmacy Drug Coverage for Treatment of Obesity (GLP-1)
    Policy CodePolicy MSA 21-49
    Change TypeCoverage restriction and new PA criteria
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document morbid obesity plus failure of other weight-loss interventions when requesting GLP-1s for obesity-only use.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage of GLP-1 medications prescribed solely to treat obesity will be reduced effective January 1, 2026.

    Clinical PA criteria will require patients to be classified as morbidly obese and to have documented failure of all other clinically appropriate weight-loss interventions, and coverage should be considered to avert need for bariatric surgery.

    Some GLP-1 medications (e.g., Saxenda and Wegovy) will become non-preferred on the Single Preferred Drug List starting January 1, 2026, affecting copayment amounts.

    Coverage for GLP-1 medications for non-obesity indications will not change.

    Jan 1, 2026effective date for coverage changes
    6 monthsexisting PAs honored
    $3 vs $1copayment non-preferred vs preferred

    Coverage Criteria for GLP-1 Medications Prescribed Solely for Obesity

    Clinical PA criteria for obesity-only GLP-1 coverage

    Covered when ALL of the following are met:

    Obesity-only GLP-1 coverage criteria: Patient is classified as morbidly obese.

    From policy: patient must be classified as morbidly obese.

    Obesity-only GLP-1 coverage criteria: There is documented failure of all other clinically appropriate weight-loss interventions, including trial and failure of Preferred Drug List (PDL) preferred anti-obesity agents.

    Coverage is contingent on documented failure of all other clinically appropriate weight-loss interventions (including trial and failure of PDL-preferred agents).

    Obesity-only GLP-1 coverage criteria: Use of the GLP-1 medication is considered only as a measure to avert the need for higher-cost bariatric surgery.

    Policy specifies coverage must be considered only to avert bariatric surgery.

    Policy Summary
    Payermclaren health plan
    PolicyUpdate of Pharmacy Drug Coverage for Treatment of Obesity (GLP-1)
    Policy CodePolicy MSA 21-49
    Change TypeCoverage restriction and new PA criteria
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document morbid obesity plus failure of other weight-loss interventions when requesting GLP-1s for obesity-only use.
    SourceLink
    On This Page
    Coverage Criteria for GLP-1 Medications Prescribed Solely for ObesityDrugs and Coding ReferencesProvider Authorization, Documentation, and Denial TriggersBackground and Policy ScopeDefinitions and Terminology

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Requests for GLP-1 receptor agonist medications submitted for indications other than treatment of obesity are not affected by this policy change and will continue to be processed according to their existing coverage criteria and indications. The policy change specifically targets GLP-1 use when prescribed solely to treat obesity; other approved uses remain covered.

    Requests for GLP-1 medications submitted solely for weight loss that do not meet the updated obesity-only clinical requirements are not covered. Specifically, coverage for obesity-only requests will be reduced effective January 1, 2026, and prior authorization for these requests will require that the patient be classified as morbidly obese and have documented failure of all other clinically appropriate weight-loss interventions; requests that lack these elements risk denial.

    Drugs and Coding References

    GLP-1 medications referencedNDC
    Liraglutidegeneric for Saxenda
    SaxendaSaxenda
    WegovyWegovy
    ZepboundZepbound
    NDC or specific codes not listedDocument lists example products but does not provide NDCs or billing codes.
    PA clinical threshold — obesity-only GLP-1 coverage
    Clinical PA thresholdPatient must be classified as morbidly obese; coverage applies only when this is documented.
    Prior-treatment failure requirementDocumented failure of all other clinically appropriate weight-loss interventions, including trial and failure of PDL‑preferred anti‑obesity agents.
    Purpose-of-therapy requirementCoverage must be considered only as a measure to avert the need for higher‑cost bariatric surgery.
    ScopeApplies to GLP‑1 medications requested solely to treat obesity (including requests for continuation) effective January 1, 2026.
    PA posting and detailsDetailed clinical PA criteria will be posted on the pharmacy website (mi.primetherapeutics.com under Clinical and PDL PA Criteria for Anti‑Obesity Agents).

    Provider Authorization, Documentation, and Denial Triggers

    Prior Authorization

    Obesity-only GLP-1 requests require prior authorization

    Prior authorization is required for GLP-1 receptor agonist medications when they are requested solely to treat obesity; clinical PA criteria will apply and be posted on the pharmacy website.

    Step Therapy

    Step therapy: must document failure of other weight‑loss interventions

    Coverage for GLP-1 medications prescribed solely for obesity is contingent on documented failure of all other clinically appropriate weight‑loss interventions, including trial and failure of PDL‑preferred anti‑obesity agents.

    Documentation Required

    PA documentation must show morbid obesity and prior‑failure history

    Clinical documentation submitted with PA requests must demonstrate the patient is classified as morbidly obese, document failure of all other clinically appropriate weight‑loss interventions (including trials of PDL‑preferred agents), and state that the medication is being considered to avert bariatric surgery.

    Denial Risk

    Denial risk if morbid obesity or prior‑failure criteria are not met

    Requests for GLP-1 medications prescribed solely for weight loss that do not meet the morbid obesity classification or lack documented failure of other weight‑loss interventions risk denial under the updated criteria.

    Background and Policy Scope

    GLP-1 receptor agonists are a drug class used for weight loss and for other clinical indications. This policy narrows Medicaid coverage for GLP-1 products when prescribed solely to treat obesity by imposing new clinical prior authorization requirements effective January 1, 2026. Under the update, obesity-only coverage will require that the patient be classified as morbidly obese, demonstrate documented failure of all other clinically appropriate weight-loss interventions (including trial and failure of PDL-preferred anti-obesity agents), and that use be considered only to avert higher-cost bariatric surgery. Existing prior authorizations approved before January 1, 2026 will be honored for the remaining six months of their authorized period.

    Definitions and Terminology

    GLP-1 receptor agonist medications
    Drug class descriptionGlucagon-like peptide-1 (GLP-1) receptor agonist medications used for treatment of obesity and other indications
    Example: liraglutideLiraglutide (generic for Saxenda) — listed as an example product
    Example: SaxendaSaxenda — example GLP-1 product referenced in policy
    Example: WegovyWegovy — example GLP-1 product referenced in policy
    Example: ZepboundZepbound — example GLP-1 product referenced in policy
    Morbidly obese
    Coverage requirementPolicy requires the patient be classified as morbidly obese for coverage of GLP-1 medications when prescribed solely to treat obesity
    Numeric BMI thresholdNo numeric BMI threshold or specific numeric definition of 'morbidly obese' is provided in the document
    Documentation expectationClinical documentation must demonstrate morbid obesity classification as part of PA requirements